深圳市东旭餐饮管理有限公司

广州润生细胞医药科技有限责任公司

Guangzhou Runsheng Cytomed Technology Co., Ltd. is a Sino-foreign joint venture biotechnology enterprise dedicated to cell medicine R&D and clinical translational research. The founder and academic leader of the company, Professor Ruan Runsheng, holds a postdoctoral degree from the University of Zurich in Switzerland, is a senior researcher at the National University of Singapore's Department of Medicine, a chief researcher at the Institute of Bioengineering and Nanotechnology of the Singapore Science and Technology Agency, and a member of the European Society of Medical Oncology (ESMO). He has also been included in the US New Century 500 Scientists and the Marquis' Who's Who Yearbook of the United States. Professor Ruan Runsheng has long been committed to the research and development of cellular immunology, with his latest achievement being the Tvac？ tumor personalized precision combined immunotherapy technology.

Founded on September 24, 2019, in Nansha, Guangzhou, the company focuses on exploring and developing the clinical applications of Tvac？ tumor personalized precision combined immunotherapy technology. This technology uses genomics, proteomics, and other omics technologies along with tumor immunology to achieve individualized precision treatment, marking an important direction for future cancer treatments.

Currently, the company has established four platforms: bioinformatics, proteomics, peptide synthesis, and cellular immunity. These platforms are equipped with high-speed local servers and cloud platforms, ultra-high-throughput 106-channel peptide synthesizers, liquid mass spectrometers, PCR instruments, Elispot, flow cytometers, RTCA, and cell culture rooms. These advanced facilities ensure robust support for the screening of new antigens and the development of peptide drugs. The company has built a highly specialized technical R&D team leveraging its platform advantages. Core team members come from prestigious institutions such as the Hong Kong University of Science and Technology, Technical University of Denmark, Stanford University School of Medicine, Harvard Medical School, and Macquarie University in Australia, all holding master's or doctoral degrees. Their expertise spans molecular biology, biochemistry, tumor immunology, clinical medicine, and industrialization.

The company has established strategic partnerships with institutions such as the National University Hospital of Singapore, Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center, the First Affiliated Hospital of Sun Yat-sen University, the Second Affiliated Hospital of Guangzhou Medical College, Guangdong Provincial People's Hospital, and Guangzhou First People's Hospital. Tvac？ technology is undergoing steady clinical trials, with smooth progress. Plans are underway to submit an NDA for Tvac？ within the next three years, aiming for formal clinical application in tumor treatment. Simultaneously, the company is advancing other tumor cell therapy R&D and clinical translation projects.

In 2021, the company partnered with the Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center to establish a postdoctoral research station, continuously attracting and nurturing high-end biomedical talent. It aims to provide a platform for international researchers pursuing the dream of medical practice.

The company is currently staffed primarily by R&D personnel, with two foreign experts, and maintains a flexible organizational structure and fresh corporate culture. It is a dynamic and energetic cell medicine R&D team with international vision and top-tier standards. Moving forward, the company will closely align with market demands, applying professional technology to medical institutions and patients, and creating an innovative technology platform that integrates scientific development, talent cultivation, and shared benefits.

北京世通仁和数码科技有限公司

北京世通仁和数码科技有限公司，规模为50-150人，类型为民营公司，行业为餐饮业。

广东木月家居有限公司

广东木月家居有限公司成立于2012年，坐落于家具之都顺德乐从，主要经营线上家具销售。截至目前，木月已入驻多个主流电商平台（如淘宝、天猫、京东、苏宁、拼多多、唯品会等），形成集研发、生产、销售和服务于一体的综合性企业，年销售额达3亿元，累计服务客户超80万人，拥有木月、weddinghome等多个注册商标，并自主研发了数百项家具外观设计专利。2016年至2017年，木月连续两年荣获京东“**突破奖”；2018年，入选CCTV“中国优选品牌”。2017年至2019年，公司年均增长率超过100%，2020年至2024年间，不断拓展新领域。

木月不仅是家具制造商，更是追求美好生活的倡导者。公司文化基于“让生活更美好”的理念，致力于通过高品质、环保及科技便捷的产品，提升人们的生活质量，使每个人的生活更加美好。

宁波探路者国际贸易有限公司

宁波探路者国际贸易有限公司，简称探路者国贸，成立于2019年，目前团队规模约20人。预计到2022年，探路者国贸将实现出口额2500万美元，主要市场集中在北美、欧洲、英国及日本，并积极扩展至东南亚与南美地区。产品涵盖室内室外家具家居用品、宠物用品、健身用品以及节日相关产品。运营模式以亚马逊平台为中心的跨境电商，已在全球设立多站点，包括美国、欧洲、英国、日本等。除亚马逊外，公司还布局于Wayfair、Newegg、Walmart等平台，并自建线上独立站。产品开发与研发持续投入，结合市场反馈优化产品与供应链管理。探路者国贸隶属于凯越国贸，后者是凯越集团的一员，集团成立于2003年底，旗下拥有逾50家出口贸易事业部与公司。凯越集团在宁波、义乌、上海设有运营中心，在广州、汕头、深圳、青岛及海外设有分支。2022年，集团进出口总额达13亿美元以上，员工总数超过2300人，服务范围覆盖全球领先零售商、知名品牌与世界500强企业，以及海外中小零售商、品牌商、进口商与电商平台。集团与全球逾200个国家和地区超过10000名海外客户保持良好合作，提供市场调研、产品研发、采购管理、包装设计、产品检测、质量控制、物流协调、采购代理融资等服务。

集团总部位于宁波，临近宁波广电集团与宁波大学西校区，办公环境优越。2013年，凯越学院成立，为员工提供培训与发展机会。薪酬体系基于业绩导向，提供绩效奖金与分红，年度表现突出者享有奖励与晋升机会。福利方面，集团为员工缴纳五险一金，发放过节费、高温补贴、婚育礼金、生日礼物，并设立公益基金“蒲公英计划”，组织年度境外旅游，为服务满十年的员工准备豪华大礼包。其他福利包括办公室下午茶、班车服务、晚下班打车报销、节假日提前放假等，旨在营造温馨的工作氛围。集团总部设于宁波、义乌、上海、广州、汕头、杭州、青岛、南京、深圳、泉州等地。

宁波探路者国际贸易有限公司（探路者国贸）成立于2019年，作为凯越国贸（凯越集团）的第十六家子公司，专注于通过亚马逊平台为主的跨境电商业务，致力于开拓北美、欧洲、英国及日本市场，并逐步拓展至东南亚和南美市场。其产品线丰富，包括室内外家具家居用品、宠物用品、健身用品和节日用品等。公司以提供高质量产品和卓越客户服务为核心价值，助力品牌在全球范围内实现增长。

凯越集团成立于2003年底，总部设在宁波，并在义乌、上海设有运营中心，在广州、汕头、深圳、青岛及部分海外国家设有分支机构。集团已发展成为宁波市和义乌市自营出口业务规模和员工人数最大的集团公司之一，2022年进出口总额达到13亿美元以上，员工总数超过2300人。集团长期服务于全球领先的零售商、世界知名的品牌客户和全球500强企业，同时也支持海外中小零售商、品牌商、进口商以及电商平台的发展。

集团注重人才培养和企业文化建设，2013年成立凯越学院，为员工提供全面的培训和发展机会。福利待遇方面，集团为员工提供五险一金、过节费、高温费、结婚/生育礼金、生日礼物等，并设立公益基金“蒲公英计划”，组织年度境外旅游活动，为服务满十年的员工准备豪华大礼包。此外，集团还提供办公室下午茶、班车服务、晚下班打车报销、节假日提前放假等贴心福利，营造了温馨和谐的工作环境。

集团总部位于宁波，地理位置优越，周边设施完善，便于员工工作和生活。集团总部和各分支机构遍布宁波、义乌、上海、广州、汕头、杭州、青岛、南京、深圳、泉州等城市，为集团在全球范围内的业务拓展提供了有力支撑。

宁波探路者国际贸易有限公司和凯越集团共同致力于通过创新的产品和服务，推动品牌全球化发展，为客户提供全方位的支持与服务，实现共赢。